AGTC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AGTC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Applied Genetic Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $10.81 Mil. Applied Genetic Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $9.34 Mil. Applied Genetic Technologies's annualized EBITDA for the quarter that ended in Sep. 2022 was $-69.52 Mil. Applied Genetic Technologies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 was -0.29.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Applied Genetic Technologies's Debt-to-EBITDA or its related term are showing as below:
During the past 11 years, the highest Debt-to-EBITDA Ratio of Applied Genetic Technologies was -0.31. The lowest was -0.43. And the median was -0.35.
The historical data trend for Applied Genetic Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied Genetic Technologies Annual Data | |||||||||||||||||||||
Trend | Jun13 | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | - | - | -0.34 | -0.43 | -0.35 |
Applied Genetic Technologies Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.38 | -0.34 | -0.47 | -0.33 | -0.29 |
For the Biotechnology subindustry, Applied Genetic Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Applied Genetic Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Applied Genetic Technologies's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Applied Genetic Technologies's Debt-to-EBITDA for the fiscal year that ended in Jun. 2022 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (10.569 | + | 11.902) | / | -64.564 | |
= | -0.35 |
Applied Genetic Technologies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (10.808 | + | 9.342) | / | -69.524 | |
= | -0.29 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2022) EBITDA data.
Applied Genetic Technologies (NAS:AGTC) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Applied Genetic Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Susan Schneider | officer: Chief Medical Officer | C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615 |
Jonathan I Lieber | officer: Chief Financial Officer | C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451 |
Stephen W Potter | officer: See Remarks | 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046 |
Gerald Anthony Reynolds | officer: Chief Accounting Officer | C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615 |
Susan B. Washer | director, officer: President and CEO | C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615 |
Hope Doyley-gay | officer: General Counsel | C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615 |
Abraham Scaria | officer: Chief Scientific Officer | C/O APPLIED GENETIC TECHNOLOGIES CORP, 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615 |
Yehia Hashad | director | C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615 |
Robinson James A. Jr. | director | 852 WINTER STREET, WALTHAM MA 02451 |
William Aliski | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Krol Patrick Johan Hendrik | 10 percent owner | GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS |
Privium Fund Management B.v. | 10 percent owner | GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS |
Aescap 2.0 Stichting | 10 percent owner | GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS |
Inspirational Visions B.v. | 10 percent owner | C/O PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, 2333 CK LEIDEN P7 2333 |
Brian Krex | officer: General Counsel | C/O AGTC, 14193 NW 119TH TERRACE, SUITE #10, ALACHUA FL 32615 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 07-13-2022
By PRNewswire PRNewswire • 11-17-2022
By PurpleRose PurpleRose • 07-11-2022
By Value_Insider Value_Insider • 12-01-2022
By PRNewswire PRNewswire • 11-14-2022
By GlobeNewswire GlobeNewswire • 10-24-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By GlobeNewswire GlobeNewswire • 10-26-2022
By PurpleRose PurpleRose • 07-13-2022
By GuruFocusNews GuruFocusNews • 07-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.